Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced presentations at World Vaccine Congress Washington 2026 in Washington, D.C., March 30–April 2, 2026. Highlights include a March 30 oral presentation of Phase 1 data on TNX-4800 for seasonal Lyme prevention and April 1 talks on TNX-801 and pox-based antigen delivery.

Speakers include Mark S. Klempner, MD, Farooq Nasar, PhD, and Christopher Cooper, PhD, with session times and rooms listed for each presentation.

News Market Reaction – TNXP

-4.60%

4 alerts

-4.60% Session close to close

+2.2% Peak Tracked

$216.36M Market Cap

1.0x Rel. Volume

In the Mar 24 session, TNXP declined 4.60%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.2% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming World Vaccine Congress presentations featuring Phase 1 data fo...

Analysis

This announcement highlights upcoming World Vaccine Congress presentations featuring Phase 1 data for TNX-4800, a long-acting monoclonal antibody for Lyme prevention, and TNX-801, a live horsepox-based vaccine candidate for smallpox and mpox. It reinforces Tonix’s infectious disease and vaccine platform alongside its CNS franchise. In context of recent earnings, financing activity, and regulatory filings, investors may watch for additional efficacy, safety, and partnering details from these sessions and how they fit with broader pipeline priorities.

Key Figures

TNX-4800 Phase: Phase 1 TNX-4800 presentation time: 10:10 a.m. ET TNX-801 presentation time: 10:10 a.m. ET +2 more

5 metrics

TNX-4800 Phase Phase 1 TNX-4800 Lyme disease monoclonal antibody data at World Vaccine Congress

TNX-4800 presentation time 10:10 a.m. ET March 30, 2026 oral presentation, Room 202B

TNX-801 presentation time 10:10 a.m. ET April 1, 2026 presentation on live attenuated MPOX vaccine, Room 202A

Modular pox session time 3:25 p.m. ET April 1, 2026 session on poxvirus antigen-delivery systems, Room 20A

Conference dates March 30–April 2, 2026 World Vaccine Congress Washington 2026 schedule

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 18	Conference presentation	Positive	+11.1%	CEO presentation at BIO-Europe Spring 2026 on CNS and immunology programs.
Mar 17	Pipeline presentations	Positive	-5.2%	AACR oral and poster data on preclinical immuno-oncology candidates and TNX-1700.
Mar 12	Earnings results	Neutral	-1.3%	Q4 and 2025 results, TONMYA launch metrics, cash position, and financings.
Mar 10	Clinical data update	Positive	+1.6%	Post hoc Phase 3 TONMYA analyses showing rapid pain relief and favorable LHH.
Mar 09	Clinical data presentation	Positive	+1.6%	Phase 3 TONMYA data at PainConnect and reminder of FDA approval and launch.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

TNXP has often reacted positively to scientific and data presentations, with one notable divergence on an AACR-related announcement.

Recent Company History

Over recent months, Tonix has highlighted multiple scientific and corporate milestones. In March 2026, it announced Phase 3 TONMYA data at AAPM and a fibromyalgia congress, both followed by modest gains of about 1.65%. Earnings on March 12, 2026 brought cash, revenue, and financing updates with a small negative move. AACR immuno-oncology presentation news on March 17 saw a -5.15% reaction, while a BIO-Europe Spring presentation announcement on March 18 was followed by an 11.13% gain, underscoring sensitivity to visibility and clinical catalysts.

Key Terms

phase 1, monoclonal antibody, borrelia burgdorferi, orthopoxvirus, +3 more

7 terms

phase 1 medical

"Monday, March 30: Phase 1 data on TNX-4800..."

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

monoclonal antibody medical

"a long-acting human monoclonal antibody (mAb) that targets..."

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

borrelia burgdorferi medical

"outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent..."

Borrelia burgdorferi is the bacterium that causes Lyme disease, transmitted to humans through certain tick bites. Think of it as a stealthy invader that can trigger long-lasting symptoms and spur demand for diagnostics, antibiotics, and potential vaccines; outbreaks or changing case patterns can affect healthcare spending, regulatory attention, and the prospects of biotech and medical-device companies working on testing or treatments, making it material to investors tracking those sectors.

orthopoxvirus medical

"the Company's attenuated, live orthopoxvirus (horsepox) vaccine candidate..."

Orthopoxvirus is a family of related viruses that infect humans and animals and can cause illnesses ranging from mild rashes to serious disease; well-known members have historically driven major public-health responses. For investors, outbreaks or renewed detection can quickly change demand for vaccines, diagnostics, treatments and related services, prompt regulatory action or government purchasing, and thus alter revenue forecasts and stock prices much like a sudden supply-and-demand shock.

mpox medical

"vaccine candidate with the potential capability to protect against smallpox and mpox."

Mpox is an infectious viral disease that causes fever, rash and swollen lymph nodes and spreads through close contact; think of it like a less common cousin of seasonal illnesses that can lead to local outbreaks. It matters to investors because outbreaks can change demand for medical supplies, affect healthcare and insurance costs, disrupt travel and workforce availability, and trigger regulatory or public health responses that influence company revenues and risk profiles.

antigen-delivery system medical

"Horsepox as a modular antigen-delivery system for broad and sustained immunity..."

An antigen-delivery system is the method or platform used to carry and present a piece of a pathogen (the antigen) to the immune system so the body learns to recognize and fight it. Think of it as a mail carrier or classroom that delivers and displays a wanted poster to train the immune system. Investors monitor these systems because their design affects how well a vaccine or therapy works, how safe it is, how easily it can be manufactured at scale, and how quickly regulators may approve it.

live virus vaccine medical

"TNX-801 (horsepox, live virus vaccine) for the prevention of smallpox and mpox"

A live virus vaccine contains a weakened form of a virus that can still reproduce a little inside the body without causing full illness, so the immune system learns to recognize and fight the real virus. Think of it like training with a tired opponent so your immune system gains real practice. For investors, these vaccines can offer strong, lasting protection but also bring higher manufacturing complexity, stricter safety and regulatory scrutiny, and different distribution and liability considerations compared with non‑replicating vaccines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease 

Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, live virus vaccine) for the prevention of smallpox and mpox

Wednesday, April 1: Horsepox as a modular antigen-delivery system for broad and sustained immunity in novel vaccines to protect against other pathogens

BERKELEY HEIGHTS, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced an oral presentation of Phase 1 data on TNX-4800 (formerly known as mAb 2217LS)^1,2, a long-acting human monoclonal antibody (mAb) that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease in humans in the U.S., at the World Vaccine Congress Washington 2026 held in Washington, D.C., March 30-April 2, 2026.

The Company’s Farooq Nasar, PhD, Director, Virology will present data on TNX-801, the Company's attenuated, live orthopoxvirus (horsepox) vaccine candidate with the potential capability to protect against smallpox and mpox. Finally, Christopher Cooper, PhD, Director, Immunology at Tonix will serve as moderator on a panel discussing modular antigen-delivery systems in novel pox-based vaccines.

TNX-4800 Presentation Details

Title: A Long-Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease
Location: Room 202B
Date and Time: March 30, 2026, 10:10 a.m. ET
Session Category: Measuring Breadth & Emerging Targets
Presenters: Mark S. Klempner, MD, Professor of Medicine at UMass Chan Medical School, inventor of TNX-4800, and Principal Investigator of the study

Other Session Details

Title: A Live Attenuated, Minimally Replicative MPOX Vaccine
Location: Room 202A, Level 2
Date and Time: April 1, 2026, 10:10 am ET
Session Category: Emerging & Re-Emerging Diseases
Presenter: Farooq Nasar, PhD, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals

Title: Poxvirus as a Modular Antigen-Delivery System for Broad and Sustained Immunity
Location: Room 20A, Level 2
Date and Time: April 1, 2026, 3:25 p.m. ET
Session Category: Emerging & Re-Emerging Diseases
Moderator: Christopher Cooper, PhD, Director, Immunology, RDC, Tonix Pharmaceuticals

About TNX-4800
TNX-4800 (formerly known as mAb 2217LS) is a human monoclonal antibody with an engineered extended half-life that targets the outer-surface protein A (OspA) on Lyme-causing Borrelia bacteria. When TNX-4800-containing blood is ingested by the tick, TNX-4800 kills and blocks the maturation of Borrelia burgdorferi in the mid-gut of infected deer ticks. The Company in-licensed TNX-4800 from UMass Chan Medical School in 2025. Published work in animals showed that TNX-4800 was 95% effective in preventing infection after a six-day challenge with ticks infected with Borrelia burgdorferi.¹ TNX-4800 was derived from mAb 2217 by amino acid substitutions in its crystallizable fragment (Fc) domain which serve to prolong the serum half-life. A single administration in the Spring is designed to potentially provide immunity within two days and maintain protective antibody titers for the entire tick season, providing pre-exposure prophylaxis against Lyme disease without relying on the recipient’s immune system to generate antibodies. By delivering a well-characterized antibody directly, TNX-4800 has been shown to block transmission of Borrelia burgdorferi from ticks to animals. TNX-4800 also sidesteps the multidose schedules required for OspA vaccines in development³ and the FDA-approved vaccine that was withdrawn from the market.⁴ The Company expects to have GMP investigational product available for clinical testing in early 2027. Pending FDA clearances, a field study is expected to initiate enrollment in the first half of 2027, and a controlled human infection model (CHIM) study in 2028.

About the TNX-4800 Phase 1 Study
TNX-4800 was studied in a randomized, double-blind, sequential dose-escalation study (NCT04863287) that evaluated safety, tolerability, pharmacokinetics (PK), and immunogenicity of TNX-4800 in healthy adults. 44 subjects were randomized, and 41 completed the study. Subjects received a single subcutaneous (SC) administration of placebo or TNX-4800 at 0.5, 1.5, 5, or 10 mg/kg. Safety was assessed via clinical and lab evaluations. Drug exposure increased by approximately 25 times for a 20 times increase in dose. Serum TNX-4800 was measurable at the earliest sampling time of 24 hours, indicating rapid systemic absorption. TNX-4800 concentrations remained quantifiable for >200 days in 80% of volunteers at the lowest dose and for up to 350 days in the majority of volunteers at higher doses (i.e., ≥ 1.5 mg/kg). Mean half-life ranged from 62-69 days across groups. Serum concentrations remained quantifiable for up to 12 months in most subjects. Mean exposure for the 10 mg/kg cohort was less than 20% of the highest exposures in a rat toxicology study. Anti-drug antibodies (ADA) were detected in <10% of treated subjects, with no impact on PK. Most adverse events were mild or moderate. TNX-4800 was determined to be generally safe and well tolerated.

About Lyme Disease 
In the United States, Lyme disease is caused by the bacterium Borrelia burgdorferi. Lyme disease remains the most common vector-borne infection in the United States, and its incidence is climbing each year, due in part to global changes in climate expanding the habitat range for ticks.⁵ It occurs most commonly in the Northeast, mid-Atlantic, and upper-Midwest regions. Lyme disease bacteria are transmitted through the bite of infected Ixodes ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, heart, and nervous system. Laboratory testing is helpful if used correctly and performed with FDA-cleared tests. Although many cases of Lyme disease can be treated successfully with antibiotics, diagnosis and treatment are often delayed or missed. Chronic Lyme is considered an Infection Associated Chronic Illness (IACI), and is a chronic, debilitating disease state characterized by joint and muscle pain, fatigue, and other symptoms.⁶

About TNX-801
TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine based on horsepox in pre-clinical development to prevent mpox and smallpox. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance. TNX-801 is in the pre-IND stages of development.

Citations
¹Schiller ZA, et al. J Clin Invest. 2021 131(11):e144843.
²Wang Y, et al. J Infect Dis. 2016. 214(2):205-11.
³Comstedt P, et al. Vaccine. 2015 33(44):5982-8.
⁴Connaught’s (ImuLyme™) and SmithKline Beecham’s (LYMErix™) Lyme disease vaccines were withdrawn. Nigrovic LE, et al. Epidemiol Infect. 2007 135(1):1-8. doi: 10.1017/S0950268806007096. Epub 2006 Aug 8. PMID: 16893489; PMCID: PMC2870557.
⁵Gomes-Solecki M, et. al. Clin Infect Dis. 2020 70(8):1768-1773. doi: 10.1093/cid/ciz872. PMID: 31620776; PMCID: PMC7155782.
⁶National Academies of Sciences, Engineering, and Medicine. 2025. Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses. Washington, DC: The National Academies Press. https://doi.org/10.17226/28578.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® SymTouch^® (sumatriptan injection 3 mg) and Tosymra^® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. In addition, the Company’s CNS portfolio includes TNX-2900 (intranasal oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including long-acting human monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contacts
Deborah Elson
Tonix Pharmaceuticals 
deborah.elson@tonixpharma.com

Ray Jordan
Putnam Insights
ray@putnaminsights.com

FAQ

When will Tonix (TNXP) present Phase 1 data on TNX-4800 at World Vaccine Congress Washington 2026?

Tonix will present Phase 1 TNX-4800 data on March 30, 2026 at 10:10 a.m. ET. According to the company, the oral presentation titled "A Long-Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease" is scheduled in Room 202B.

What is TNX-4800 (mAb 2217LS) that Tonix (TNXP) is presenting on March 30, 2026?

TNX-4800 is a long-acting human monoclonal antibody targeting OspA for seasonal Lyme disease prevention. According to the company, the Phase 1 data will be presented by Mark S. Klempner, MD, the study's principal investigator.

What will Tonix (TNXP) present about TNX-801 at the conference on April 1, 2026?

Tonix will present animal and in vitro studies on TNX-801, an attenuated live horsepox vaccine candidate, on April 1, 2026 at 10:10 a.m. ET. According to the company, Farooq Nasar, PhD, will present in Room 202A.

What session will discuss poxvirus as an antigen-delivery system presented by Tonix (TNXP)?

Tonix will moderate a session on poxvirus as a modular antigen-delivery system on April 1, 2026 at 3:25 p.m. ET. According to the company, Christopher Cooper, PhD, will serve as moderator in Room 20A, Level 2.

Who are the Tonix speakers for the World Vaccine Congress Washington 2026 presentations (TNXP)?

Tonix speakers include Mark S. Klempner, MD; Farooq Nasar, PhD; and Christopher Cooper, PhD. According to the company, each will present or moderate sessions on March 30 and April 1, 2026 at designated rooms and times.

Where and when is World Vaccine Congress Washington 2026 where Tonix (TNXP) will present?

World Vaccine Congress Washington 2026 runs March 30–April 2, 2026 in Washington, D.C. According to the company, Tonix presentations are March 30 and April 1 with specific room locations and session times provided.